Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

EU Approval Verdicts Near For A Bumper Crop Of New Drugs

Executive Summary

Novartis, Arvelle, AstraZeneca and Incyte are among a raft of drug sponsors who should find out shortly whether the European Medicines Agency will vote in favor of approving their products for use in the EU.

You may also be interested in...



13 New Drugs Pass Muster At The EMA, Dexamethasone Withdrawal Explained

New products from Paion, Arvelle, Incyte and many others have been recommended for approval by the European Medicines Agency. Meanwhile, the agency has explained why the EU marketing authorization application for Dexamethasone Taw, for treating COVID-19 patients, was withdrawn.

Novartis Wins EU Thumbs Up for MS Treatment

Kesimpta could become the first and only self-administered, targeted B-cell therapy for patients in Europe with relapsing forms of multiple sclerosis.

AstraZeneca Vaccine May Only Gain EU Approval In Under 70s

AZ and the EU are at loggerheads over supplies of the COVID-19 vaccine. On top of that, its marketing authorization will present dilemmas.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS143686

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel